Flywire Officially Files for US IPO, Seeks to Raise $100M in Funding
3 hours ago by Benjamin Godfrey · 3 min read
Photo: Flywire / Facebook
You have successfully joined our subscriber list.
Flywire has revealed a couple of underwriters including but not limited to Goldman Sachs and JPMorgan Chase & Co.
Boston, Massachusetts-based payment firm Flywire Corporation has officially filed for an Initial Public Offering (IPO) in the United States of America. As reported by Morning Star, the company seeks to raise $100 million from investors, a benchmark figure that may be quite conservative for the firm.
Flywire IPO comes amidst growing interest in fintech and payments in general. The past year has facilitated a high level of growth in the payment industry. The COVID-19 pandemic pushed people to embrace alternative ways to conduct cash transactions when compared to what the traditional markets have to offer. Flywire has been one of the beneficiaries of this growth, with revenues
Eastern Insurance Group LLC Acquires Assets of Barr Insurance Agency, Inc
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
First Trust IPOX-100 Index Fund ETF (ETF:FPX), (IPO) - Biotech Firms Gyroscope Therapeutics, Talaris Therapeutics Set IPO Terms
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
1 Introduction Forward-lookingstatements This Annual Report and the Consolidated Financial Statements contain forward-looking statements as defined under U.S. federal securities laws. Forward-looking statements are based on our current expectations of future events and many of these statements can be identified using terminology such as believes, expects, anticipates, plans, may, will, projects, continues, estimates, potential, opportunity and similar expressions. These forward-looking statements, which include, but are not limited to, statements related to the COVID-19 coronavirus pandemic, our collaboration and license agreement with CSL Behring LLC and the timing of the completion of the transactions contemplated thereby, our beliefs about competitive advantage and the capabilities of our manufacturing facility, our cash runway, the advancement of clinical trials, our intellectual property portfolio, and the impact of regul